CRESCENT BIOPHARMA, INC. Operating Lease Cost
CRESCENT BIOPHARMA, INC. (CBIO) reported Operating Lease Cost of $324.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-26
- CRESCENT BIOPHARMA, INC. operating lease, cost for the quarter ending 2025-03-31 was $557.00, a 99.70% decline year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, cost for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, cost for the quarter ending 2024-09-30 was $68.70K, a 73.06% decline year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, cost for the quarter ending 2024-06-30 was $188.31K, a 23.87% decline year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, cost for fiscal 2025 was $324.00K, a 28.04% decline from fiscal 2024.
- CRESCENT BIOPHARMA, INC. operating lease, cost for fiscal 2024 was $450.27K, a 52.35% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. operating lease, cost for fiscal 2023 was $944.96K, a 1.83% increase from fiscal 2022.
- CRESCENT BIOPHARMA, INC. operating lease, cost for fiscal 2022 was $927.96K, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $324.00K 10-K · filed 2026-02-26 | ||||
| 2025-03-31 | $557.00 10-Q · filed 2025-05-14 | $557.00 derived: sum of 2 quarters · filed 2026-02-26 | $69.26K derived: sum of 3 quarters · filed 2026-02-26 | $257.57K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | $68.70K derived: sum of 2 quarters · filed 2026-02-26 | $257.01K derived: sum of 3 quarters · filed 2026-02-26 | $450.27K 10-K · filed 2025-02-13 | |
| 2024-09-30 | $68.70K 10-Q · filed 2024-11-13 | $257.01K derived: sum of 2 quarters · filed 2024-11-13 | $445.32K 10-Q · filed 2024-11-13 | $655.89K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $188.31K 10-Q · filed 2024-08-08 | $376.62K 10-Q · filed 2024-08-08 | $587.19K derived: sum of 3 quarters · filed 2025-05-14 | $842.23K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-03-31 | $188.31K 10-Q · filed 2025-05-14 | $398.88K derived: sum of 2 quarters · filed 2025-05-14 | $653.92K derived: sum of 3 quarters · filed 2025-05-14 | $901.28K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $210.57K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $465.61K derived: sum of 2 quarters · filed 2025-02-13 | $712.97K derived: sum of 3 quarters · filed 2025-02-13 | $944.96K 10-K · filed 2025-02-13 | |
| 2023-09-30 | $255.04K 10-Q · filed 2024-11-13 | $502.40K derived: sum of 2 quarters · filed 2024-11-13 | $734.39K 10-Q · filed 2024-11-13 | $966.38K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $247.36K 10-Q · filed 2024-08-08 | $479.35K 10-Q · filed 2024-08-08 | $711.34K derived: sum of 3 quarters · filed 2024-08-08 | $943.33K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $231.99K 10-Q · filed 2023-05-03 | $463.98K derived: sum of 2 quarters · filed 2024-03-27 | $695.97K derived: sum of 3 quarters · filed 2024-03-27 | $927.96K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-12-31 | $231.99K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $463.98K derived: sum of 2 quarters · filed 2024-03-27 | $695.97K derived: sum of 3 quarters · filed 2024-03-27 | $927.96K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $231.99K 10-Q · filed 2023-11-03 | $463.98K derived: sum of 2 quarters · filed 2023-11-03 | $695.97K 10-Q · filed 2023-11-03 | $927.96K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-06-30 | $231.99K 10-Q · filed 2023-08-02 | $463.98K 10-Q · filed 2023-08-02 | $695.97K derived: sum of 3 quarters · filed 2024-03-27 | $927.96K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-03-31 | $231.99K 10-Q · filed 2023-05-03 | $463.98K derived: sum of 2 quarters · filed 2024-03-27 | $695.97K derived: sum of 3 quarters · filed 2024-03-27 | $927.96K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2021-12-31 | $231.99K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $463.98K derived: sum of 2 quarters · filed 2024-03-27 | $695.97K derived: sum of 3 quarters · filed 2024-03-27 | $927.96K 10-K · filed 2024-03-27 | $927.96M 10-K · filed 2022-03-03 |
| 2021-09-30 | $231.99K 10-Q · filed 2022-11-09 | $463.98K derived: sum of 2 quarters · filed 2022-11-09 | $695.97K 10-Q · filed 2022-11-09 | $927.96K derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-06-30 | $231.99K 10-Q · filed 2022-08-03 | $463.98K 10-Q · filed 2022-08-03 | $695.97K derived: sum of 3 quarters · filed 2023-03-29 | $927.96K derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-03-31 | $231.99K 10-Q · filed 2022-04-28 | $463.98K derived: sum of 2 quarters · filed 2023-03-29 | $695.97K derived: sum of 3 quarters · filed 2023-03-29 | $927.96K derived: sum of 4 quarters · filed 2023-03-29 | |
| 2020-12-31 | $231.99K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $463.98K derived: sum of 2 quarters · filed 2023-03-29 | $695.97K derived: sum of 3 quarters · filed 2023-03-29 | $927.96K 10-K · filed 2023-03-29 | |
| 2020-09-30 | $231.99K 10-Q · filed 2021-11-02 | $463.98K derived: sum of 2 quarters · filed 2021-11-02 | $695.97K 10-Q · filed 2021-11-02 | $927.96M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-06-30 | $231.99K 10-Q · filed 2021-08-05 | $463.98K 10-Q · filed 2021-08-05 | $927.73M derived: sum of 3 quarters · filed 2022-03-03 | $927.96M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-03-31 | $231.99K 10-Q · filed 2021-05-03 | $927.49M derived: sum of 2 quarters · filed 2022-03-03 | $927.73M derived: sum of 3 quarters · filed 2022-03-03 | $927.96M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2019-12-31 | $927.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $927.49M derived: sum of 2 quarters · filed 2022-03-03 | $927.73M derived: sum of 3 quarters · filed 2022-03-03 | $927.96M 10-K · filed 2022-03-03 | $927.96K 10-K · filed 2020-02-28 |
| 2019-09-30 | $231.99K 10-Q · filed 2020-11-06 | $464.02K derived: sum of 2 quarters · filed 2020-11-06 | $695.97K 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $232.04K 10-Q · filed 2020-07-31 | $464.03K 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $231.99K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |